The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Market Value Of The Kesimpta Market Projected To Expand During 2026–2030?
Historically, the expansion witnessed can be attributed to the limitations of conventional multiple sclerosis treatments, rising rates of MS diagnosis, advancements in monoclonal antibody science, the adoption of B-cell targeting by neurologists, and the demand for more convenient dosing methods.
The projected growth during the forecast period is expected to result from the expanding population affected by relapsing multiple sclerosis, a greater embrace of home injection therapies, the extension of treatments to progressive forms of MS, enhanced patient adherence to medical regimens, and increasing investment in neurology healthcare.
Significant trends anticipated for this period include a move towards B cell depleting therapies, a growing preference for self-administered MS treatments, an increase in early intervention for multiple sclerosis, the rising application of targeted immunotherapies, and the expansion of neurology care delivered in home environments.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20126&type=smp
What Are The Main Drivers Accelerating The Growth Of The Kesimpta Market?
The anticipated rise in the incidence of multiple sclerosis (MS) is set to enhance the expansion of the kesimpta market in the coming years. Multiple sclerosis is a long-term autoimmune condition impacting the central nervous system, leading to the deterioration of nerve fibers and resulting in symptoms such as muscle weakness, visual disturbances, and cognitive decline. This growing prevalence of MS is attributed to factors like advanced diagnostic methods, increased public awareness, and more efficient reporting mechanisms. Kesimpta addresses relapsing forms of MS by specifically targeting B-cells, which helps in reducing relapse episodes and slowing the advancement of disability. For example, as reported in August 2025 by Neurologia i Neurochirurgia Polska, a peer-reviewed medical journal from Poland, MS incidence in China is observed to be increasing, with yearly estimates ranging from 0.2 to 0.6 per 100,000 people. Similarly, in Turkey, the MS incidence rate in 2022 was 6.2 per 100,000 people, and in Saudi Arabia, recent projections indicate rising MS incidence rates of between 3 and 5 per 100,000 people annually. Consequently, the increasing occurrence of multiple sclerosis is a significant factor propelling the growth of the kesimpta market.
How Is The Kesimpta Market Structured Across Different Market Segments?
The kesimpta market covered in this report is segmented –
1) By Indication: Treatment Of Rhabdomyosarcoma (RMS), Treatment Of Clinically Isolated Syndrome (CIS), Treatment Of Active Secondary Progressive Multiple Sclerosis (SPMS)
2) By Formulation: Injectable formulation, Pre-filled Syringes Or Autoinjectors
3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Neurology Clinics
What Trends Are Influencing The Kesimpta Market?
A significant development in the Kesimpta market involves its self-administered, targeted B-cell therapy for addressing relapsing forms of multiple sclerosis (RMS). Kesimpta’s self-administered, targeted B-cell therapy presents an efficient and convenient treatment option for relapsing forms of multiple sclerosis (RMS), helping to lessen relapses and decelerate the disease’s progression. For instance, in April 2024, Novartis AG, a pharmaceutical company located in Switzerland, recently unveiled six-year efficacy data for its multiple sclerosis medicine, Kesimpta (ofatumumab), underscoring substantial advantages for individuals with relapsing multiple sclerosis (RMS) who are newly diagnosed and treatment-naïve. This information stems from the ALITHIOS open-label extension study, which highlights the critical importance of early intervention in the management of this chronic ailment.
Which Industry Players Are Present In The Kesimpta Market?
Major companies operating in the kesimpta market are Novartis AG
Access The Complete Kesimpta Market Report:
https://www.thebusinessresearchcompany.com/report/kesimpta-global-market-report
Which Region Holds The Largest Share In The Kesimpta Market?
North America was the largest region in the kesimpta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kesimpta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model